OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)

PHASE3CompletedINTERVENTIONAL
Enrollment

1,100

Participants

Timeline

Start Date

December 31, 2003

Primary Completion Date

December 31, 2005

Study Completion Date

December 31, 2005

Conditions
Chronic Obstructive Pulmonary DiseaseCOPD
Interventions
DRUG

Roflumilast

Trial Locations (40)

Unknown

ALTANA Pharma, Cities in Alabama

ALTANA Pharma, Cities in Arizona

ALTANA Pharma, Cities in Arkansas

ALTANA Pharma, Cities in California

ALTANA Pharma, Cities in Colorado

ALTANA Pharma, Cities in Connecticut

ALTANA Pharma, Cities in Florida

ALTANA Pharma, Cities in Georgia

ALTANA Pharma, Cities in Illionois

ALTANA Pharma, Cities in Iowa

ALTANA Pharma, Cities in Kentucky

ALTANA Pharma, Cities in Louisiana

ALTANA Pharma, Cities in Massachusetts

ALTANA Pharma, Cities in Minnesota

ALTANA Pharma, Cities in Missouri

ALTANA Pharma, Cities in Montana

ALTANA Pharma, Cities in Nebraska

ALTANA Pharma, Cities in Nevada

ALTANA Pharma, Cities in New Hampshire

ALTANA Pharma, Cities in New Jersey

ALTANA Pharma, Cities in New York

ALTANA Pharma, Cities in North Carolina

ALTANA Pharma, Cities in Ohio

ALTANA Pharma, Cities in Oklahoma

ALTANA Pharma, Cities in Oregon

ALTANA Pharma, Cities in Pennsylvania

ALTANA Pharma, Cities in Rhode Island

ALTANA Pharma, Cities in South Carolina

ALTANA Pharma, Cities in Tennessee

ALTANA Pharma, Cities in Texas

ALTANA Pharma, Cities in Utah

ALTANA Pharma, Cities in Vermont

ALTANA Pharma, Cities in Virginia

ALTANA Pharma, Cities in West Virginia

ALTANA Pharma, Cities in Wisconsin

ALTANA Pharma, Cities in Canada

ALTANA Pharma, Cities in France

ALTANA Pharma, Cities in Germany

ALTANA Pharma, Cities in Poland

ALTANA Pharma, Cities in South Africa

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY